Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Pierce

Showing results (361-370 of 385) with videos related to

Pageof 39
Sort By:
Journal of Immunology (Baltimore, Md. : 1950)|November 6, 2016
The Regulation of Inherently Autoreactive VH4-34-Expressing B Cells in Individuals Living in a Malaria-Endemic Area of West AfricaGeoffrey T Hart, Munir Akkaya, Asiya S Chida, et al.
The Journal of Infectious Diseases|January 19, 2013
A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized, double-blind clinical trialAnna P Durbin, Beth D Kirkpatrick, Kristen K Pierce, et al.
Nature Communications|May 25, 2021
Immunotranscriptomic profiling the acute and clearance phases of a human challenge dengue virus serotype 2 infection modelJohn P Hanley, Huy A Tu, Julie A Dragon, et al.
The Journal of Infectious Diseases|February 26, 2026
Safety, tolerability, and pharmacokinetics of 6-diazo-5-oxo-L-norleucine (DON) in Malawian adults with and without malaria: a Phase I dose-escalation clinical trialBrittany A Riggle, Athanasios Chamzas, Mathangi Gopalakrishnan, et al.
Plos Pathogens|May 27, 2010
The Plasmodium falciparum-specific human memory B cell compartment expands gradually with repeated malaria infectionsGreta E Weiss, Boubacar Traore, Kassoum Kayentao, et al.
Clinical & Translational Immunology|October 19, 2020
Kinetics and isotype assessment of antibodies targeting the spike protein receptor-binding domain of severe acute respiratory syndrome-coronavirus-2 in COVID-19 patients as a function of age, biological sex and disease severityNancy R Graham, Annalis N Whitaker, Camilla A Strother, et al.
Plos One|March 4, 2014
Tempol, an intracellular antioxidant, inhibits tissue factor expression, attenuates dendritic cell function, and is partially protective in a murine model of cerebral malariaIvo M B Francischetti, Emile Gordon, Bruna Bizzarro, et al.
Plos Pathogens|September 12, 2014
Plasmodium falciparum infection induces expression of a mosquito salivary protein (Agaphelin) that targets neutrophil function and inhibits thrombosis without impairing hemostasisMichael Waisberg, Alvaro Molina-Cruz, Daniella M Mizurini, et al.
NPJ Vaccines|August 15, 2017
A malaria vaccine protects <i>Aotus</i> monkeys against virulent <i>Plasmodium falciparum</i> infectionPrakash Srinivasan, G Christian Baldeviano, Kazutoyo Miura, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 22, 2009
Campylobacter jejuni strain CG8421: a refined model for the study of Campylobacteriosis and evaluation of Campylobacter vaccines in human subjectsDavid R Tribble, Shahida Baqar, Marya P Carmolli, et al.
Pageof 39

Showing results (361-370 of 385) with videos related to

Sort By:
Pageof 39
Journal of Immunology (Baltimore, Md. : 1950)|November 6, 2016
The Regulation of Inherently Autoreactive VH4-34-Expressing B Cells in Individuals Living in a Malaria-Endemic Area of West AfricaGeoffrey T Hart, Munir Akkaya, Asiya S Chida, et al.
The Journal of Infectious Diseases|January 19, 2013
A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized, double-blind clinical trialAnna P Durbin, Beth D Kirkpatrick, Kristen K Pierce, et al.
Nature Communications|May 25, 2021
Immunotranscriptomic profiling the acute and clearance phases of a human challenge dengue virus serotype 2 infection modelJohn P Hanley, Huy A Tu, Julie A Dragon, et al.
The Journal of Infectious Diseases|February 26, 2026
Safety, tolerability, and pharmacokinetics of 6-diazo-5-oxo-L-norleucine (DON) in Malawian adults with and without malaria: a Phase I dose-escalation clinical trialBrittany A Riggle, Athanasios Chamzas, Mathangi Gopalakrishnan, et al.
Plos Pathogens|May 27, 2010
The Plasmodium falciparum-specific human memory B cell compartment expands gradually with repeated malaria infectionsGreta E Weiss, Boubacar Traore, Kassoum Kayentao, et al.
Clinical & Translational Immunology|October 19, 2020
Kinetics and isotype assessment of antibodies targeting the spike protein receptor-binding domain of severe acute respiratory syndrome-coronavirus-2 in COVID-19 patients as a function of age, biological sex and disease severityNancy R Graham, Annalis N Whitaker, Camilla A Strother, et al.
Plos One|March 4, 2014
Tempol, an intracellular antioxidant, inhibits tissue factor expression, attenuates dendritic cell function, and is partially protective in a murine model of cerebral malariaIvo M B Francischetti, Emile Gordon, Bruna Bizzarro, et al.
Plos Pathogens|September 12, 2014
Plasmodium falciparum infection induces expression of a mosquito salivary protein (Agaphelin) that targets neutrophil function and inhibits thrombosis without impairing hemostasisMichael Waisberg, Alvaro Molina-Cruz, Daniella M Mizurini, et al.
NPJ Vaccines|August 15, 2017
A malaria vaccine protects <i>Aotus</i> monkeys against virulent <i>Plasmodium falciparum</i> infectionPrakash Srinivasan, G Christian Baldeviano, Kazutoyo Miura, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 22, 2009
Campylobacter jejuni strain CG8421: a refined model for the study of Campylobacteriosis and evaluation of Campylobacter vaccines in human subjectsDavid R Tribble, Shahida Baqar, Marya P Carmolli, et al.
Pageof 39